文献速递肾癌与肾肿瘤前列腺癌膀胱癌与上尿路尿路上皮癌

2022年世界卫生组织泌尿系统及男性生殖器官肿瘤分类——A部分:肾、阴茎和睾丸肿瘤

The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
PubMed 文献 · Eur Urol · 2022-07-16

本文综述2022年第五版世界卫生组织(WHO)泌尿生殖系统肿瘤分类(WHO「蓝皮书」)中肾、阴茎和睾丸肿瘤的重要修订,包括采用分层分类、引入分子驱动的肾肿瘤分类(如SMARCB1缺陷型髓样癌、TFEB改变型癌等)、阴茎鳞状细胞癌按HPV关联与否分组、新增阴囊肿瘤章节,以及睾丸肿瘤命名的保留与变更。

要点

  • 第五版WHO分类采用分层分类,按部位、类别、家族和类型列出肿瘤。
  • 肾肿瘤引入分子驱动分类,包括SMARCB1缺陷型髓样癌、TFEB改变型癌、ALK重排癌和ELOC突变癌。
  • 嗜酸性实性和囊性肾细胞癌是新定义的形态学肾细胞癌实体。

核心结论

  • 第五版WHO泌尿系统肿瘤分类(2022年)对肾、阴茎和睾丸肿瘤进行了重要修订,引入分子驱动分类和命名变更。

研究设计与样本

  • 本文为综述,总结2022年第五版WHO泌尿生殖系统肿瘤分类(蓝皮书)中肾、阴茎和睾丸肿瘤的相关变更。

主要发现

  • 肾肿瘤引入分子驱动分类,新增SMARCB1缺陷型髓样肾细胞癌、TFEB改变型肾细胞癌、ALK重排肾细胞癌和ELOC突变肾细胞癌。
  • 嗜酸性实性和囊性肾细胞癌是新定义的形态学肾细胞癌实体。
  • 阴茎鳞状细胞癌的多样形态学模式分为HPV相关和HPV无关,并尝试简化形态学分类。
  • 新增阴囊肿瘤章节。
  • 睾丸肿瘤主要命名保留,包括原位生殖细胞肿瘤(GCNIS)用于大多数生殖细胞肿瘤的癌前病变,并与非GCNIS来源的肿瘤区分。

关键数值与推荐

  • 第五版WHO分类包含「必要和期望的诊断标准」部分,代表形态学诊断标准,并结合免疫组化和相关分子检测。
  • 分子驱动肾肿瘤分类纳入肾肿瘤基因组学最新发现。
  • 阴茎鳞状细胞癌按HPV关联与否分组。
  • 睾丸肿瘤中,大多数生殖细胞肿瘤的癌前病变使用「原位生殖细胞肿瘤」(GCNIS)术语,并与非GCNIS来源的肿瘤区分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The fifth edition of the World Health Organization (WHO) classification of urogenital tumours (WHO "Blue Book"), published in 2022, contains significant revisions. This review summarises the most relevant changes for renal, penile, and testicular tumours. In keeping with other volumes in the fifth edition series, the WHO classification of urogenital tumours follows a hierarchical classification and lists tumours by site, category, family, and type. The section "essential and desirable diagnostic criteria" included in the WHO fifth edition represents morphologic diagnostic criteria, combined with immunohistochemistry and relevant molecular tests. The global introduction of massive parallel sequencing will result in a diagnostic shift from morphology to molecular analyses. Therefore, a molecular-driven renal tumour classification has been introduced, taking recent discoveries in renal tumour genomics into account. Such novel molecularly defined epithelial renal tumours include SMARCB1-deficient medullary renal cell carcinoma (RCC), TFEB-altered RCC, Alk-rearranged RCC, and ELOC-mutated RCC. Eosinophilic solid and cystic RCC is a novel morphologically defined RCC entity. The diverse morphologic patterns of penile squamous cell carcinomas are grouped as human papillomavirus (HPV) associated and HPV independent, and there is an attempt to simplify the morphologic classification. A new chapter with tumours of the scrotum has been introduced. The main nomenclature of testicular tumours is retained, including the use of the term "germ cell neoplasia in situ" (GCNIS) for the preneoplastic lesion of most germ cell tumours and division from those not derived from GCNIS. Nomenclature changes include replacement of the term "primitive neuroectodermal tumour" by "embryonic neuroectodermal tumour" to separate these tumours clearly from Ewing sarcoma. The term "carcinoid" has been changed to "neuroendocrine tumour", with most examples in the testis now classified as "prepubertal type testicular neuroendocrine tumour".

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2022. PMID: 35853783. doi:10.1016/j.eururo.2022.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。